Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 135673-97-1 | MDL No. : | MFCD00065614 |
Formula : | C24H27NO4 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | HIJAUEZBPWTKIV-QFIPXVFZSA-N |
M.W : | 393.48 | Pubchem ID : | 978326 |
Synonyms : |
|
Num. heavy atoms : | 29 |
Num. arom. heavy atoms : | 12 |
Fraction Csp3 : | 0.42 |
Num. rotatable bonds : | 8 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 2.0 |
Molar Refractivity : | 111.9 |
TPSA : | 75.63 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | Yes |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | Yes |
CYP2C9 inhibitor : | Yes |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | Yes |
Log Kp (skin permeation) : | -4.6 cm/s |
Log Po/w (iLOGP) : | 3.07 |
Log Po/w (XLOGP3) : | 5.78 |
Log Po/w (WLOGP) : | 4.95 |
Log Po/w (MLOGP) : | 3.65 |
Log Po/w (SILICOS-IT) : | 4.14 |
Consensus Log Po/w : | 4.32 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -5.7 |
Solubility : | 0.000787 mg/ml ; 0.000002 mol/l |
Class : | Moderately soluble |
Log S (Ali) : | -7.14 |
Solubility : | 0.0000287 mg/ml ; 0.0000000729 mol/l |
Class : | Poorly soluble |
Log S (SILICOS-IT) : | -6.29 |
Solubility : | 0.000201 mg/ml ; 0.000000511 mol/l |
Class : | Poorly soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 3.0 |
Synthetic accessibility : | 4.14 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: The substrate attached to the resin (mmol calculated from the substrate loading procedure) was weighted into a 2 mL syringe fitted with porous polyethylene filter. The Fmoc group was removed (if necessary) by treatment with 20% piperidine in DMF (2 × 1.5 mL, 10 + 15 min) and the resin was washed with DMF (4 × 1.5 mL, 4 × 1 min). Coupling of the appropriate (Fmoc protected) amino acid was performed by agitation overnight in DMF (2 mL), (benzotriazol-1-yloxy)tripyrrolidinophosphonium hexafluorophosphate (PyBOP) (2 equiv) and DIPEA (6 equiv). The resin was washed with DMF (4 × 1.5 mL, 4 × 1 min) and subsequently Fmoc-deprotected and washed as described above. Finally, after three or four coupling procedures, the tetrazole derivative (9) was attached as described in the General procedure for attaching the tetrazole carboxylate. After completion of the coupling cycles, the resin was washed with several portions of DMF, CH2Cl2, and finally MeOH before it was dried in vacuo. The peptide was cleaved of the resin by treatment with TFA (95% aq, 2.5 mL) and Et3SiH (100 muL) for 2 h in a capped tube. The resin was filtered off and washed with TFA (3 × 0.5 mL). The filtrate was collected in a centrifuge tube and concentrated in a stream of N2 (g). Cold diethyl ether (12 mL) was used to precipitate the product as a TFA-salt, which was collected by centrifugation, washed with cold diethyl ether (2 × 3 mL) and dried. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
95% | The molecular scaffold 3 was synthesized using standard solid-phase peptide synthesis methods. The 2-chlorotrityl-chloride resin (Novabiochem, loading 1.4 mmol/g) was used as solid support. For loading of the resin (100 mg, 0.14 mmol) 2 equiv. Fmoc-protected amino acid and 3 equiv. DIPEA (74 mul, 0.42 mmol) were dissolved in 2 ml CH2Cl2 and the reaction mixture was added to the resin. The reaction mixture was shaken overnight at room temperature. The resin was washed three times with 2 ml CH2Cl2 and 2 ml DMF. For Fmoc-deprotection the resin was treated two times for 15 min. with 2 ml 30 percent piperidine/DMF. A standard protocol was used for solid phase peptide synthesis: 4 equiv. Fmoc-protected amino acid, 4 equiv. HBTU (212 mg, 0.56 mmol), 4 equiv. HOBt (76 mg, 0.56 mmol) and 8 equiv. DIPEA (196 ml, 1.12 mmol) were dissolved in 2 ml CH2Cl2/DMF (1/1; v/v). The reaction mixture was stirred 20 min. at room temperature and then added to the resin. The reaction mixture was shaken for 2 hours at room temperature.For the cleavage of the peptide 3 from the solid-phase the resin was treated two times for 15 min. with 2 ml 2 percent TFA/CH2Cl2 (v/v). The solvent was co-evaporated with toluene under reduced pressure and the product was purified by preparative HPLC (H2O + 0.1 percent TFA; 10-95 percent CH3CN, 15 min, 120 ml/min, column: Sun Fire 50x100 mm, Waters). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
2.7 mg | [Example 25] (Synthesis method Y): Production of Ac-[D-Pro24,Pya(4)26,Cha27,36,Aib28,31,Lys (Hexyl)30]-PYY(23-36) (compound No. 279) Synthesis of Ac- [D-Pro24,Pya(4)26,Cha27,36,Aib28,31,Lys(Hexyl)30]-PYY(23-36) (0322) H-Aib-Thr(But)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Rink Amide resin (89.7 mg, 0.02 mmol) synthesized in Example 23 was weighed and placed in a reaction vessel, washed with DMF and, after swelling, treated with Fmoc-Lys(Mtt)-OH (125.0 mg, 0.2 mmol), 0.5 M HOAt/DMF solution (0.4 mL, 0.2 mmol), DIPCDI (31.8 muL, 0.2 mmol) for 15 hr to introduce Lys(Mtt) residue. The obtained resin was washed with toluene, treated with TFA-triisopropylsilane-trifluoroethanol-toluene (1:5:47:47) for 10 min, and an operation to remove the reaction solution was repeated until the solution was no longer colored. The resin was washed with toluene, neutralized by washing with 5% DIEA-toluene solution, and washed with DMF. The obtained resin was suspended in DMF, 1-hexanal (2.5 muL, 0.04 mmol) was added in the presence of acetic acid (50 muL) and the mixture was stirred for 15 min. NaBH3CN (6.2 mg, 0.1 mmol) was added, and the mixture was further stirred for 1.5 hr. The resin was washed with DMF, and treated with Boc2O (24.4 mg, 0.2 mmol), DIEA (34.8 muL, 0.2 mmol) in DMF at room temperature for 3 hr. The progress of the reaction was confirmed by Kaiser test, and Asn(Trt), Aib, Cha, Pya(4), Arg(Pbf), D-Pro, Ser(But) were successively introduced by manual solid phase synthesis process including repeats of removal of Fmoc by 20% piperidine/DMF treatment and condensation by a treatment with Fmoc-amino acid (0.1 mmol), 0.5 M HOAt/DMF (0.2 mL, 0.1 mmol), DIPCDI (16 muL, 0.1 mmol). Then, after removal of Fmoc, the resin was treated with Ac2O (9.4 muL), DIEA (17.4 muL) in DMF for 30 min for acetylation, and the obtained resin was washed with MeOH and dried. (0323) The obtained resin (103.9 mg) was treated with TFA: thioanisole: m-cresol: HO: EDT: TIS (80:5:5:5:2.5:2.5) (1 mL) for 90 min, an operation to add diethyl ether to the reaction solution, precipitate a white powder by centrifugation, and remove diethyl ether by decantation was repeated twice. The residue was dissolved in aqueous acetic acid solution, passed through a disc filter with a pore diameter 0.45 mum to remove fine granules, and purified by preparative HPLC using Daisopak-SP100-5-ODS-P 2×25 cm, and Solution A: 0.1% TFA-water, Solution B: 0.1% TFA-containing acetonitrile, flow rate 8 mL/min, A/B: 73/27-63/37 linear density gradient elution (60 min) was performed. The eluted object product was fractionated in test tubes, and each fraction was analyzed by HPLC to specify fractions containing only the object product. They were combined and freeze-dried to give 2.7 mg of a white powder. MALDI-TOF-MS analysis, (M+H)1891.9 (Calculated 1892.2) HPLC elution time: 9.6 min elution condition (HPLC mode d): column: Merck Chromolith Performance RP-18e(4.6×100 mm I.D.) eluent: using Solution A: 0.1% TFA-water, Solution B: 0.1% TFA-containing acetonitrile, A/B: 80/20 - 30/70 linear concentration gradient elution (25 min) flow rat: 1.0 mL/min |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
4.1 mg | The obtained resin (89.7 mg, 0.02 mmol) was weighed and placed in a reaction vessel, washed with DMF and, after swelling, treated with Fmoc-Lys(Mtt)-OH (125.0 mg, 0.2 mmol), 0.5 M HOAt/DMF solution (0.4 mL, 0.2 mmol), DIPCDI (31.8 muL, 0.2 mmol) for 15 hr to introduce Lys(Mtt) residue. The obtained resin was washed with toluene, treated with TFA-triisopropylsilane-trifluoroethanol-toluene (1:5:47:47) for 10 min, and an operation to remove the reaction solution was repeated until the solution was no longer colored. The resin was washed with toluene, neutralized by washing with 5% DIEA-toluene solution, washed again with toluene. To the obtained resin was added N,N-bis-Boc-1-guanylpyrazole (31.0 mg, 0.1 mmol), DIEA (17.4 muL, 0.1 mmol), in toluene:TFE (3:1), and treated at room temperature overnight. The progress of the reaction was confirmed by Kaiser test, and Asn(Trt), Aib, Cha, Pya(4), Arg(Pbf), D-Pro, Ser(Bu) were successively introduced by manual solid phase synthesis process including repeats of removal of Fmoc by 20% piperidine/DMF treatment and condensation by a treatment with Fmoc-amino acid (0.1 mmol), 0.5 M HOAt/DMF (0.2 mL, 0.1 mmol), DIPCDI (16 muL, 0.1 mmol). Then, after removal of Fmoc, the resin was treated with AcO (9.4 muL), DIEA (17.4 muL) in DMF for 30 min for acetylation, and the obtained resin was washed with MeOH and dried. The obtained resin (87.1 mg) was treated with TFA: thioanisole: m-cresol: HO: EDT: TIS (80:5:5:5:2.5:2.5) (1 mL) for 90 min, an operation to add diethyl ether to the reaction solution, precipitate a white powder by centrifugation, and remove ether by decantation was repeated twice. The residue was dissolved in aqueous acetic acid solution, passed through a disc filter with a pore diameter 0.45 mum to remove fine granules, and purified by preparative HPLC using Daisopak-SP100-5-ODS-P 2×25 cm, and Solution A: 0.1% TFA-water, Solution B: 0.1% TFA-containing acetonitrile, flow rate 8 mL/min, A/B: 78/22-68/32 linear concentration gradient elution (60 min) was performed. The eluted object product was fractionated in test tubes, and each fraction was analyzed by HPLC to specify fractions containing only the object product. They were combined and freeze-dried to give 4.1 mg of a white powder. MALDI-TOF-MS analysis, (M+H)1850.3 (Calculated 1850.1) HPLC elution time: 7.4 min elution condition (HPLC mode d): column: Merck Chromolith Performance RP-18e(4.6×100 mm I.D.) eluent: using Solution A: 0.1% TFA-water, Solution B: 0.1% TFA-containing acetonitrile, A/B: 80/20 - 30/70 linear concentration gradient elution (25 min) flow rate: 1.0 mL/min |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
5.1 mg | [Example 24] (Synthesis method X): Production of Ac-[D-Pro24,Pya(4)26,Cha27,36,Aib28,31,Lys(Ac)30]-PYY(23-36) (compound No. 278) Synthesis of Ac-[D-Pro24,Pya(4)26,Cha27,36,Aib28,31,Lys(Ac)30]-PYY (23-36) (0321) H-Aib-Thr (But) -Arg (Pbf) -Gln(Trt)-Arg(Pbf)-Cha-Rink Amide resin (89.7 mg, 0.02 mmol) synthesized in Example 23 was weighed and placed in a reaction vessel, washed with DMF and, after swelling, treated with Fmoc-Lys(Mtt)-OH (125.0 mg, 0.2 mmol), 0.5 M HOAt/DMF solution (0.4 mL, 0.2 mmol), DIPCDI (31.8 muL, 0.2 mmol) for 15 hr to introduce Lys(Mtt) residue. The obtained resin was washed with toluene, treated with TFA-triisopropylsilane-trifluoroethanol-toluene (1:5:47:47) for 10 min, and an operation to remove the reaction solution was repeated until the solution was no longer colored. The resin was washed with toluene, neutralized by washing with 5% DIEA-toluene solution, washed with DMF, and the obtained resin was treated overnight with AcO (9.4 muL), DIEA (17.4 muL) in DMF at room temperature. The progress of the reaction was confirmed by Kaiser test, and Asn(Trt), Aib, Cha, Pya(4), Arg(Pbf), D-Pro, Ser(Bu) were successively introduced by manual solid phase synthesis process including repeats of removal of Fmoc by 20% piperidine/DMF treatment and condensation by a treatment with Fmoc-amino acid (0.1 mmol), 0.5 M HOAt/DMF (0.2 mL, 0.1 mmol), DIPCDI (16 muL, 0.1 mmol). Then, after removal of Fmoc, the resin was treated with AcO (9.4 muL), DIEA (17.4 muL) in DMF for 30 min for acetylation, and the obtained resin was washed with MeOH and dried. The obtained resin (102.8 mg) was treated with TFA: thioanisole: m-cresol: HO: EDT: TIS (80:5:5:5:2.5:2.5) (1 mL) for 90 min, an operation to add diethyl ether to the reaction solution, precipitate a white powder by centrifugation and remove ether by decantation was repeated twice. The residue was dissolved in aqueous acetic acid solution, passed through a disc filter with a pore diameter 0.45 mum to remove fine granules, and purified by preparative HPLC using Daisopak-SP100-5-ODS-P 2×25 cm, and Solution A: 0.1% TFA-water, Solution B:. 0.1% TFA-containing acetonitrile, flow rate 8 mL/min, A/B: 77/23-67/33 linear concentration gradient elution (60 min) was performed. The eluted object product was fractionated in test tubes, and each fraction was analyzed by HPLC to specify fractions containing only the object product. They were combined and freeze-dried to give 5.1 mg of a white powder. MALDI-TOF-MS analysis, (M+H)1850.2 (Calculated 1850.1) HPLC elution time: 8.0 min elution condition (HPLC mode d): column: Merck Chromolith Performance RP-18e(4.6×100 mm I.D.) eluent: using Solution A: 0.1% TFA-water, Solution B: 0.1% TFA-containing acetonitrile, A/B: 80/20 - 30/70 linear concentration gradient elution (25 min) flow rate: 1.0 mL/min |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
515 mg | Synthesis of tetrahydro-2H-pyran-4-ylcarbamoyl-[D-Pro24,Pya(4)26,Cha27,36,Aib28,31,Lys30]-PYY(23-36) (0317) H-Asn(Trt)-Lys(Boc)-Aib-Thr(But)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Sieber Amide resin (0.289 mmol/g, 1.73 g, 0.5 mmol) obtained by condensing amino acids in the same manner as in Example 12 and using Sieber Amide resin as a starting material, ABI433A peptide synthesizer DCC/HOBt 0.25 mmol protocol was swollen with DMF. Then, the resin was treated with Fmoc-Aib-OH (651 mg, 2.0 mmol), HOAt in DMF (0.5 M, 4.0 mL, 2.0 mmol), DIPCDI (318 muL, 2.0 mmol) for 1.5 hr. Fmoc group was removed with 20% piperidine in DMF, and the resin was treated with Fmoc-Cha-OH (787 mg, 2.0 mmol), HOAt in DMF (0.5 M, 4.0 mL, 2.0 mmol), DIPCDI (318 muL, 2.0 mmol) for 1.5 hr. The resin was washed, and further treated overnight with Fmoc-Cha-OH (787 mg, 2.0 mmol), HOAt in DMF (0.5 M, 4.0 mL, 2.0 mmol), DIPCDI (318 muL, 2.0 mmol). The resin was washed, and subjected to a capping treatment with decanoic anhydride (737 muL, 2. 0 mmol), DIEA (348 muL, 2.0 mmol) in DMF for 30 min. Fmoc group was removed with 20% piperidine in DMF, and the resin was treated with Fmoc-Pya(4)-OH (767 mg, 2.0 mmol), HOAt in DMF (0.5 M, 4.0 mL, 2.0 mmol), DIEA (348 muL, 2.0 mmol), DIPCDI (318 muL, 2.0 mmol) for 2.5 hr. The resin was washed with DMF, Fmoc group was removed with 20% piperidine in DMF, and the resin was treated with Fmoc-Arg(Pbf)-OH (1.30 g, 2.0 mmol), HOAt in DMF (0.5 M, 4.0 mL, 2.0 mmol), DIPCDI (318 muL, 2.0 mmol) for 2 hr. The resin was washed, and subjected to a capping treatment with decanoic anhydride (737 muL, 2.0 mmol), DIEA (348 muL, 2.0 mmol) in DMF for 30 min. Fmoc group was removed with 20% piperidine in DMF, and the resin was treated with Fmoc-D-Pro-OH (674 mg, 2.0 mmol), HOAt in DMF (0.5 M, 4.0 mL, 2.0 mmol), DIPCDI (318 muL, 2.0 mmol) for 12 hr. The resin was washed, and further treated overnight with Fmoc-D-Pro-OH (674 mg, 2.0 mmol), HOAt in DMF (0.5 M, 4.0 mL, 2.0 mmol), DIPCDI (318 muL, 2.0 mmol). The resin was washed, and subjected to a capping treatment with decanoic anhydride (737 muL, 2.0 mmol), DIEA (348 muL, 2.0 mmol) in DMF for 30 min. The resin was washed with DMF, Fmoc group was removed with 20% piperidine in DMF, and the resin was treated with Fmoc-Ser(But)-OH (767 mg, 2.0 mmol), HOAt in DMF (0.5 M, 4.0 mL, 2.0 mmol), DIPCDI (318 muL, 2.0 mmol) for 2 hr. The resin was washed successively with DMF, MeOH, and dried under reduced pressure. The total amount of the obtained H-Ser(But)-D-Pro-Arg(Pbf)-Pya(4)-Cha-Aib-Asn(Trt)-Lys(Boc)-Aib-Thr(But)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Sieber Amide resin was swollen again with DMF, and treated with CDI (405 mg, 2.5 mmol), DIEA (436 muL, 2.5 mmol) in DMF for 2 hr. The resin was washed with DMF, and treated overnight with 4-aminotetrahydropyrane (404 mg, 4.0 mmol) in DMF. The resin was washed successively with DMF, MeOH, dried under reduced pressure and the total amount of the obtained resin was suspended in TFA: thioanisole: m-cresol: H2O: EDT: TIS (80:5:5:5:2.5:2.5) (15 mL), and the mixture was stirred at room temperature for 4 hr. The reaction solution was added to stirring diethyl ether under ice-cooling while removing the resin by a filter to obtain precipitation, and an operation to remove the supernatant after centrifugation was repeated 3 times. The residue was extracted with 50% aqueous acetic acid solution, passed through a disc filter with a pore diameter 0.45 mum to remove fine granules, and purified in 9 portions by HPLC. The HPLC conditions were YMC Pack R&D-ODS-5-B S-5 120A column (30x250 mm), Solution A: 0.1% TFA-water, Solution B: 0.1% TFA-containing acetonitrile, flow rate 15 mL/min, A/B: 77/23-67/33 linear concentration gradient elution (60 min). Each fraction was analyzed by HPLC to specify fractions containing only the object product. The fractions with low purity obtained by the first purification were concentrated, and subjected to HPLC separation in 2 portions under the same conditions. All the fractions containing only the object product were combined and freeze-dried to give 685 mg of a white powder. The obtained purified sample (685 mg) was dissolved in CHCN/HO (15/30 mL), and AG 1x8 AcO resin (7.54 mL, 9.05 mmol equivalents) was added. The solution was stood for 1 hr while occasionally stirring with hand, passed through a disc filter with a pore diameter 0.45 mum to remove fine granules, concentrated in an evaporator to reduce the liquid amount to about 5 mL, and the solution was freeze-dried to give 515 mg of a white powder. MALDI-TOF-MS analysis, (M+H)1893.2 (Calculated 1893.1) HPLC elution time: 7.5 min elution condition (HPLC mode g): column: SHISEIDO CAPCELL PAK C18 MGII(4.6×100 mm) eluent: using Solution A: 0.1% TFA-water, Solution B: 0.1% TFA-containing acetonitrile, A/B: 80/20 - 30/70 linear concentration gradient elution (25 min) flow rate: 1.0 mL/min |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
186.1 mg | Example 29] (0337) (Synthesis method AC): Production of Ac-[D-Hyp24,Iva25,28,Pya(4)26,Cha27,36,Lys30,Aib31]-PYY(23-36) (compound No. 298) Compound No. 298: (0338) Synthesis of Ac-[D-Hyp24,Iva25,28,Pya(4)26,Cha27,36,Lys30,Aib31]-PYY (23-36) (0339) H-Asn(Trt)-Lys(Boc)-Aib-Thr(But)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Sieber Amide resin (SEQ ID NO:177) (952.8 mg, 0.25 mmol) obtained in Example 20 was weighed and placed in a reaction vessel, washed with DMF, and stirred in DMF for 20 min to swell the resin. Then, the resin was treated with <strong>[857478-30-9]Fmoc-Iva-OH</strong> (339.4 mg, 1 mmol), 0.5 M HOAt/DMF solution (2 mL, 1 mmol), DIPCDI (159 muL, mmol) for 120 min. The N-terminal Fmoc group was removed by 20percent piperidine/DMF treatment. By a similar procedure, Cha was introduced. In the same manner, removal of Fmoc group and condensation were repeated to introduce Pya(4), Iva, D-Hyp, Ser(But). After removal of Fmoc, the obtained resin was treated with AcOSu (157.1 mg, 1 mmol), DIEA (174.2 muL, 1 mmol) in DMF for 60 min, and washed with MeOH and dried to give Ac-Ser(But)-D-Hyp-Iva-Pya(4)-Cha-Iva-Asn(Trt)-Lys(Boc)-Aib-Thr(But)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Sieber Amide resin (1.1162 g). The obtained resin (1.1162 g) was treated with TFA: thioanisole: m-cresol: H2O: EDT: TIS (80:5:5:5:2.5:2.5) (6 mL) for 120 min, an operation to add diethyl ether to the reaction solution, precipitate a white powder by centrifugation, and remove diethyl ether by decantation was repeated twice. The residue was dissolved in aqueous acetic acid solution, passed through a disc filter with a pore diameter 0.45 mum to remove fine granules, and concentrated in an evaporator. After confirmation of the purity of the obtained crude peptide solution by HPLC, the peptide was purified by preparative HPLC in 6 portions using Daisopak-SP100-5-ODS-P 2×25 cm, and Solution A: 0.1percent TFA-water, Solution B: 0.1percent TFA-containing acetonitrile, flow rate 8 mL/min, A/B: 75/25-65/35 linear concentration gradient elution (60 min) was performed. The eluted object product was fractionated in test tubes, and each fraction was analyzed by HPLC to specify fractions containing only the object product. They were combined and freeze-dried to give 250.2 mg of a white powder. (0340) The obtained purified sample (250.2 mg, 140.47 mumol) was dissolved in water (20 mL), and AG 1x8 AcO resin (2.34 mL, 2.81 mmol equivalents) was added. The solution was stood for 1 hr while occasionally stirring with hand, passed through a disc filter with a pore diameter 0.45 mum to remove fine granules, concentrated in an evaporator to reduce the liquid amount to about 5 mL, and the solution was freeze-dried by cooling in a dry ice bath to give 186.1 mg of a white powder. MALDI-TOF-MS analysis, (M+H)1780.6 (Calculated 1781.1) HPLC elution time: 9.2 min elution condition (HPLC mode d): column: Merck Chromolith Performance RP-18e(4.6×100 mm I.D.) eluent: using Solution A: 0.1percent TFA-water, Solution B: 0.1percent TFA-containing acetonitrile, A/B: 80/20 - 30/70 linear concentration gradient elution (25 min) flow rate: 1.0 mL/min |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
303.2 mg | Example 31] (Synthesis method AE): Production of 4-Imidazolecarbonyl-[D-Hyp24,Iva25,Pya(4)26,Cha27,36,Leu(Me)28,Lys30,Aib31]-PYY(23-36) (compound No. 336) Compound No. 336: (0342) Synthesis of 4-imidazolecarbonyl-[D-Hyp24,Iva25,Pya(4)26,Cha27,36,Leu(Me)28, Lys30,Aib31]-PYY(23-36) (0343) H-Asn (Trt) -Lys (Boc) -Aib-Thr(But) -Arg (Pbf) -Gln(Trt)-Arg(Pbf)-Cha-Sieber Amide resin (1.795 g, 0.5 mmol) obtained in Example 20 was weighed and placed in a reaction vessel, washed with DMF, and stirred in DMF for 20 min to swell the resin. Then, the resin was treated with Fmoc-Leu(Me)-OH (734.8 mg, 2 mmol), 0.5 M HOAt/DMF solution (4 mL, 2 mmol), DIPCDI (0.318 mL, 2 mmol) for 120 min to introduce Leu(Me) residue. The N-terminal Fmoc group was removed by 20% piperidine/DMF treatment. By a similar procedure, Cha was introduced. In the same manner, removal of Fmoc group and condensation were repeated to introduce Pya(4), Iva. The obtained resin was washed with MeOH and dried to give H-Iva-Pya(4)-Cha-Leu(Me)-Asn(Trt)-Lys(Boc)-Aib-Thr(But)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Sieber Amide resin (SEQ ID NO:181) (2.1612 g). In this case, for introduction of Pya(4) residue, DIEA (348.4 muL, 2 mmol) was added to the reaction solution during condensation. The obtained resin (1.0806 g, 0.25 mmol) was washed with DMF and, after swelling, treated with Fmoc-D-Hyp-OH (353.4 mg, 1 mmol), 0.5 M HOAt/DMF solution (2 mL, 1 mmol), DIPCDI (159 muL, 1 mmol) for 15 hr to introduce D-Hyp. Fmoc group was removed, and Ser(But) was similarly introduced. After removal of Fmoc from the obtained Fmoc-Ser(But)-D-Hyp-Iva-Pya(4)-Cha-Leu(Me)-Asn(Trt)-Lys(Boc)-Aib-Thr (But) -Arg (Pbf) -Gln (Trt) -Arg (Pbf) -Cha-Sieber amide resin, the resin was treated with 1-trityl-1H-imidazole-4-carboxylic acid (354.4 mg, 1 mmol), DIPCDI (159 muL, 1 mmol) in DMSO (1 mL), 0.5 M HOAt/DMF solution (2 mL, 1 mmol) for 120 min, and the resin was washed and dried. The obtained resin (1.2067 g) was treated with TFA: thioanisole: m-cresol: H2O: EDT: TIS (80:5:5:5:2.5:2.5) (6 mL) for 120 min, an operation to add diethyl ether to the reaction solution, precipitate a white powder by centrifugation, and remove diethyl ether by decantation was repeated twice. The residue was dissolved in aqueous acetic acid solution, passed through a disc filter with a pore diameter 0.45 mum to remove fine granules, and concentrated in an evaporator. After confirmation of the purity of the obtained crude peptide solution by HPLC, the peptide was purified by preparative HPLC in 6 portions using Daisopak-SP100-5-ODS-P 2×25 cm, and Solution A: 0.1% TFA-water, Solution B: 0.1% TFA-containing acetonitrile, flow rate 8 mL/min, A/B: 74/26-64/36 linear concentration gradient elution (60 min) was performed. The eluted object product was fractionated in test tubes, and each fraction was analyzed by HPLC to specify fractions containing only the object product. They were combined and freeze-dried to give 365.5 mg of a white powder. (0344) The obtained purified sample (365.5 mg, 196.38 mumol) was dissolved in water (30 mL), and AG 1x8 AcO resin (4.09 mL, 4.91 mmol equivalents) was added. The solution was stood for 1 hr while occasionally stirring with hand, passed through a disc filter with a pore diameter 0.45 mum to remove fine granules, concentrated in an evaporator to reduce the liquid amount to about 5 mL, and the solution was freeze-dried by cooling in a dry ice bath to give 303.2 mg of a white powder. MALDI-TOF-MS analysis, (M+H)1860.9 (Calculated 1861.1) HPLC elution time: 9.9 min elution condition (HPLC mode d): column: Merck Chromolith Performance RP-18e(4.6×100 mm I.D.) eluent: using Solution A: 0.1% TFA-water, Solution B: 0.1% TFA-containing acetonitrile, A/B: 80/20 - 30/70 linear concentration gradient elution (25 min) flow rate: 1.0 mL/min |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: In a reaction vessel, Fmoc-protected Rink amide MBHA resinwas first swelled in DMF for fifteen min. A solution of 20percent piperidinein DMF was added and mixture shaken mechanically for15 min resulting in the removal of Fmoc group. The required Fmocprotected amino acids and coupling reagent 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) were placed in amino acid vessels sequentially. DMF was added to theamino acid vessel, which was subsequently added (by positivepressure of N2) to the reaction vessel containing the resin, followedby addition of N,N-diisppropylethylamine (DIEA). After 3 h of mechanicalshaking at ambient temperature, the solvent was drainedand the resin washed with DMF (3 x 5 min) followed by methanol(2 x 5 mL). The cycles of deprotection and coupling were repeatedtill the desired peptide chain length was obtained. The resin-boundpeptide was transferred to a round bottom flask, and simultaneousremoval of resin and protective groups was achieved by using acocktail combination of TFA:triisopropylsilane (TIPS):H2O[95:2.5:2.5] for 3 h. The crude peptide was filtered and purified onpreparative HPLC system, and analyzed using solvent system ofCH3CN-H2O-0.1percent CF3COOH in the gradient system: 30 min gradient,30-100percent CH3CN-H2O-0.1percent CF3COOH at 215 nm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: In a reaction vessel, Fmoc-protected Rink amide MBHA resinwas first swelled in DMF for fifteen min. A solution of 20percent piperidinein DMF was added and mixture shaken mechanically for15 min resulting in the removal of Fmoc group. The required Fmocprotected amino acids and coupling reagent 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) were placed in amino acid vessels sequentially. DMF was added to theamino acid vessel, which was subsequently added (by positivepressure of N2) to the reaction vessel containing the resin, followedby addition of N,N-diisppropylethylamine (DIEA). After 3 h of mechanicalshaking at ambient temperature, the solvent was drainedand the resin washed with DMF (3 x 5 min) followed by methanol(2 x 5 mL). The cycles of deprotection and coupling were repeatedtill the desired peptide chain length was obtained. The resin-boundpeptide was transferred to a round bottom flask, and simultaneousremoval of resin and protective groups was achieved by using acocktail combination of TFA:triisopropylsilane (TIPS):H2O[95:2.5:2.5] for 3 h. The crude peptide was filtered and purified onpreparative HPLC system, and analyzed using solvent system ofCH3CN-H2O-0.1percent CF3COOH in the gradient system: 30 min gradient,30-100percent CH3CN-H2O-0.1percent CF3COOH at 215 nm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: In a reaction vessel, Fmoc-protected Rink amide MBHA resinwas first swelled in DMF for fifteen min. A solution of 20percent piperidinein DMF was added and mixture shaken mechanically for15 min resulting in the removal of Fmoc group. The required Fmocprotected amino acids and coupling reagent 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) were placed in amino acid vessels sequentially. DMF was added to theamino acid vessel, which was subsequently added (by positivepressure of N2) to the reaction vessel containing the resin, followedby addition of N,N-diisppropylethylamine (DIEA). After 3 h of mechanicalshaking at ambient temperature, the solvent was drainedand the resin washed with DMF (3 x 5 min) followed by methanol(2 x 5 mL). The cycles of deprotection and coupling were repeatedtill the desired peptide chain length was obtained. The resin-boundpeptide was transferred to a round bottom flask, and simultaneousremoval of resin and protective groups was achieved by using acocktail combination of TFA:triisopropylsilane (TIPS):H2O[95:2.5:2.5] for 3 h. The crude peptide was filtered and purified onpreparative HPLC system, and analyzed using solvent system ofCH3CN-H2O-0.1percent CF3COOH in the gradient system: 30 min gradient,30-100percent CH3CN-H2O-0.1percent CF3COOH at 215 nm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: In a reaction vessel, Fmoc-protected Rink amide MBHA resinwas first swelled in DMF for fifteen min. A solution of 20percent piperidinein DMF was added and mixture shaken mechanically for15 min resulting in the removal of Fmoc group. The required Fmocprotected amino acids and coupling reagent 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) were placed in amino acid vessels sequentially. DMF was added to theamino acid vessel, which was subsequently added (by positivepressure of N2) to the reaction vessel containing the resin, followedby addition of N,N-diisppropylethylamine (DIEA). After 3 h of mechanicalshaking at ambient temperature, the solvent was drainedand the resin washed with DMF (3 x 5 min) followed by methanol(2 x 5 mL). The cycles of deprotection and coupling were repeatedtill the desired peptide chain length was obtained. The resin-boundpeptide was transferred to a round bottom flask, and simultaneousremoval of resin and protective groups was achieved by using acocktail combination of TFA:triisopropylsilane (TIPS):H2O[95:2.5:2.5] for 3 h. The crude peptide was filtered and purified onpreparative HPLC system, and analyzed using solvent system ofCH3CN-H2O-0.1percent CF3COOH in the gradient system: 30 min gradient,30-100percent CH3CN-H2O-0.1percent CF3COOH at 215 nm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: In a reaction vessel, Fmoc-protected Rink amide MBHA resinwas first swelled in DMF for fifteen min. A solution of 20percent piperidinein DMF was added and mixture shaken mechanically for15 min resulting in the removal of Fmoc group. The required Fmocprotected amino acids and coupling reagent 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) were placed in amino acid vessels sequentially. DMF was added to theamino acid vessel, which was subsequently added (by positivepressure of N2) to the reaction vessel containing the resin, followedby addition of N,N-diisppropylethylamine (DIEA). After 3 h of mechanicalshaking at ambient temperature, the solvent was drainedand the resin washed with DMF (3 x 5 min) followed by methanol(2 x 5 mL). The cycles of deprotection and coupling were repeatedtill the desired peptide chain length was obtained. The resin-boundpeptide was transferred to a round bottom flask, and simultaneousremoval of resin and protective groups was achieved by using acocktail combination of TFA:triisopropylsilane (TIPS):H2O[95:2.5:2.5] for 3 h. The crude peptide was filtered and purified onpreparative HPLC system, and analyzed using solvent system ofCH3CN-H2O-0.1percent CF3COOH in the gradient system: 30 min gradient,30-100percent CH3CN-H2O-0.1percent CF3COOH at 215 nm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: In a reaction vessel, Fmoc-protected Rink amide MBHA resinwas first swelled in DMF for fifteen min. A solution of 20percent piperidinein DMF was added and mixture shaken mechanically for15 min resulting in the removal of Fmoc group. The required Fmocprotected amino acids and coupling reagent 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) were placed in amino acid vessels sequentially. DMF was added to theamino acid vessel, which was subsequently added (by positivepressure of N2) to the reaction vessel containing the resin, followedby addition of N,N-diisppropylethylamine (DIEA). After 3 h of mechanicalshaking at ambient temperature, the solvent was drainedand the resin washed with DMF (3 x 5 min) followed by methanol(2 x 5 mL). The cycles of deprotection and coupling were repeatedtill the desired peptide chain length was obtained. The resin-boundpeptide was transferred to a round bottom flask, and simultaneousremoval of resin and protective groups was achieved by using acocktail combination of TFA:triisopropylsilane (TIPS):H2O[95:2.5:2.5] for 3 h. The crude peptide was filtered and purified onpreparative HPLC system, and analyzed using solvent system ofCH3CN-H2O-0.1percent CF3COOH in the gradient system: 30 min gradient,30-100percent CH3CN-H2O-0.1percent CF3COOH at 215 nm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: In a reaction vessel, Fmoc-protected Rink amide MBHA resinwas first swelled in DMF for fifteen min. A solution of 20percent piperidinein DMF was added and mixture shaken mechanically for15 min resulting in the removal of Fmoc group. The required Fmocprotected amino acids and coupling reagent 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) were placed in amino acid vessels sequentially. DMF was added to theamino acid vessel, which was subsequently added (by positivepressure of N2) to the reaction vessel containing the resin, followedby addition of N,N-diisppropylethylamine (DIEA). After 3 h of mechanicalshaking at ambient temperature, the solvent was drainedand the resin washed with DMF (3 x 5 min) followed by methanol(2 x 5 mL). The cycles of deprotection and coupling were repeatedtill the desired peptide chain length was obtained. The resin-boundpeptide was transferred to a round bottom flask, and simultaneousremoval of resin and protective groups was achieved by using acocktail combination of TFA:triisopropylsilane (TIPS):H2O[95:2.5:2.5] for 3 h. The crude peptide was filtered and purified onpreparative HPLC system, and analyzed using solvent system ofCH3CN-H2O-0.1percent CF3COOH in the gradient system: 30 min gradient,30-100percent CH3CN-H2O-0.1percent CF3COOH at 215 nm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: In a reaction vessel, Fmoc-protected Rink amide MBHA resinwas first swelled in DMF for fifteen min. A solution of 20percent piperidinein DMF was added and mixture shaken mechanically for15 min resulting in the removal of Fmoc group. The required Fmocprotected amino acids and coupling reagent 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) were placed in amino acid vessels sequentially. DMF was added to theamino acid vessel, which was subsequently added (by positivepressure of N2) to the reaction vessel containing the resin, followedby addition of N,N-diisppropylethylamine (DIEA). After 3 h of mechanicalshaking at ambient temperature, the solvent was drainedand the resin washed with DMF (3 x 5 min) followed by methanol(2 x 5 mL). The cycles of deprotection and coupling were repeatedtill the desired peptide chain length was obtained. The resin-boundpeptide was transferred to a round bottom flask, and simultaneousremoval of resin and protective groups was achieved by using acocktail combination of TFA:triisopropylsilane (TIPS):H2O[95:2.5:2.5] for 3 h. The crude peptide was filtered and purified onpreparative HPLC system, and analyzed using solvent system ofCH3CN-H2O-0.1percent CF3COOH in the gradient system: 30 min gradient,30-100percent CH3CN-H2O-0.1percent CF3COOH at 215 nm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: In a reaction vessel, Fmoc-protected Rink amide MBHA resinwas first swelled in DMF for fifteen min. A solution of 20percent piperidinein DMF was added and mixture shaken mechanically for15 min resulting in the removal of Fmoc group. The required Fmocprotected amino acids and coupling reagent 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) were placed in amino acid vessels sequentially. DMF was added to theamino acid vessel, which was subsequently added (by positivepressure of N2) to the reaction vessel containing the resin, followedby addition of N,N-diisppropylethylamine (DIEA). After 3 h of mechanicalshaking at ambient temperature, the solvent was drainedand the resin washed with DMF (3 x 5 min) followed by methanol(2 x 5 mL). The cycles of deprotection and coupling were repeatedtill the desired peptide chain length was obtained. The resin-boundpeptide was transferred to a round bottom flask, and simultaneousremoval of resin and protective groups was achieved by using acocktail combination of TFA:triisopropylsilane (TIPS):H2O[95:2.5:2.5] for 3 h. The crude peptide was filtered and purified onpreparative HPLC system, and analyzed using solvent system ofCH3CN-H2O-0.1percent CF3COOH in the gradient system: 30 min gradient,30-100percent CH3CN-H2O-0.1percent CF3COOH at 215 nm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: In a reaction vessel, Fmoc-protected Rink amide MBHA resinwas first swelled in DMF for fifteen min. A solution of 20percent piperidinein DMF was added and mixture shaken mechanically for15 min resulting in the removal of Fmoc group. The required Fmocprotected amino acids and coupling reagent 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) were placed in amino acid vessels sequentially. DMF was added to theamino acid vessel, which was subsequently added (by positivepressure of N2) to the reaction vessel containing the resin, followedby addition of N,N-diisppropylethylamine (DIEA). After 3 h of mechanicalshaking at ambient temperature, the solvent was drainedand the resin washed with DMF (3 x 5 min) followed by methanol(2 x 5 mL). The cycles of deprotection and coupling were repeatedtill the desired peptide chain length was obtained. The resin-boundpeptide was transferred to a round bottom flask, and simultaneousremoval of resin and protective groups was achieved by using acocktail combination of TFA:triisopropylsilane (TIPS):H2O[95:2.5:2.5] for 3 h. The crude peptide was filtered and purified onpreparative HPLC system, and analyzed using solvent system ofCH3CN-H2O-0.1percent CF3COOH in the gradient system: 30 min gradient,30-100percent CH3CN-H2O-0.1percent CF3COOH at 215 nm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: In a reaction vessel, Fmoc-protected Rink amide MBHA resinwas first swelled in DMF for fifteen min. A solution of 20percent piperidinein DMF was added and mixture shaken mechanically for15 min resulting in the removal of Fmoc group. The required Fmocprotected amino acids and coupling reagent 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate (TBTU) were placed in amino acid vessels sequentially. DMF was added to theamino acid vessel, which was subsequently added (by positivepressure of N2) to the reaction vessel containing the resin, followedby addition of N,N-diisppropylethylamine (DIEA). After 3 h of mechanicalshaking at ambient temperature, the solvent was drainedand the resin washed with DMF (3 x 5 min) followed by methanol(2 x 5 mL). The cycles of deprotection and coupling were repeatedtill the desired peptide chain length was obtained. The resin-boundpeptide was transferred to a round bottom flask, and simultaneousremoval of resin and protective groups was achieved by using acocktail combination of TFA:triisopropylsilane (TIPS):H2O[95:2.5:2.5] for 3 h. The crude peptide was filtered and purified onpreparative HPLC system, and analyzed using solvent system ofCH3CN-H2O-0.1percent CF3COOH in the gradient system: 30 min gradient,30-100percent CH3CN-H2O-0.1percent CF3COOH at 215 nm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
All peptides were synthesized in the same manner following thesynthesis procedure for 4-imidazolecarbonyl-[D-Hyp24,Iva25,Pya(4)26,Cha27,36,cMeLeu28,Lys30,Aib31]PYY(23-36) (31). Using a commerciallyavailable Sieber amide resin (391 mg, 0.25 mmol) as astarting material and the ABI 433A peptide synthesizer (DCC/HOBt0.25-mmol protocol), amino acids were successively condensed togive H-Asn(Trt)-Lys(Boc)-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-NH-Sieber Amide Resin (903 mg, 0.289 mmol/g). A 34.6-mg(0.01 mmol) aliquot of the obtained resin was weighed, washedwith DMF, and after swelling, treated with Fmoc-cMeLeu-OH(18.4 mg, 0.05 mmol), DIPCDI (8.0 lL, 0.05 mmol), and 0.5 MHOAt/DMF (0.1 mL, 0.05 mmol) in DMF for 90 min to introducecMeLeu residue on position 28. The resin was treated with 20%piperidine/DMF to remove N-terminal Fmoc group, then Cha wasintroduced on position 27 in the same manner. Pya(4), Iva,D-Hyp, Ser(tBu) and N-terminal 1-trityl-1H-imidazole-4-carboxylicacid were introduced by repeating the same steps. The resin waswashed with DMF, methanol, and dried to give 1-trityl-1Himidazole-4-carbonyl-Ser(tBu)-D-Hyp-Iva-Pya(4)-Cha-cMeLeu-Asn(Trt)-Lys(Boc)-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Sieberamide resin (43.0 mg, 0.01 mmol). Trifluoroacetic acid (TFA):thioanisole:m-cresol:H2O:1,2-ethanedithiol:triisopropylsilane (80:5:5:5:2.5:2.5) (0.4 mL) was added to the entire amount of the obtainedresin, then the mixture was stirred at ambient temperature for90 min, and diethyl ether was added to the reaction solution to allowprecipitation of a white powder. Diethyl ether was removed bydecantation after centrifugation of the suspension, and the procedurewas repeated to remove acid and the scavenger. The residuewas extracted with an aqueous acetic acid solution and purified bypreparative HPLC using a Daisopak-SP100-5-ODS-P column(250 20mmi.d.) to give 5.1 mgof a white powder. Mass spectrum:MALDI-TOF (a-cyano-4-hydroxycinnaminic acid, monoisotopic) [M+H]+ 1861.25 (calcd. 1861.09). Elution time on RP-HPLC: 6.43 min.Elution conditions: a Phenomenex Kinetex XB-C18 column(1.7 mm, 100 2.1 mm i.d.), linear density-gradient elution witheluents A/B = 95/5-45/55 (10 min) using 0.1% TFA in water as eluentA and 0.1% TFA-containing acetonitrile as eluent B; flow rate:0.5 mL/min. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: All peptides were synthesized in the same manner following thesynthesis procedure for 4-imidazolecarbonyl-[D-Hyp24,Iva25,Pya(4)26,Cha27,36,cMeLeu28,Lys30,Aib31]PYY(23-36) (31). Using a commerciallyavailable Sieber amide resin (391 mg, 0.25 mmol) as astarting material and the ABI 433A peptide synthesizer (DCC/HOBt0.25-mmol protocol), amino acids were successively condensed togive H-Asn(Trt)-Lys(Boc)-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-NH-Sieber Amide Resin (903 mg, 0.289 mmol/g). A 34.6-mg(0.01 mmol) aliquot of the obtained resin was weighed, washedwith DMF, and after swelling, treated with Fmoc-cMeLeu-OH(18.4 mg, 0.05 mmol), DIPCDI (8.0 lL, 0.05 mmol), and 0.5 MHOAt/DMF (0.1 mL, 0.05 mmol) in DMF for 90 min to introducecMeLeu residue on position 28. The resin was treated with 20%piperidine/DMF to remove N-terminal Fmoc group, then Cha wasintroduced on position 27 in the same manner. Pya(4), Iva,D-Hyp, Ser(tBu) and N-terminal 1-trityl-1H-imidazole-4-carboxylicacid were introduced by repeating the same steps. The resin waswashed with DMF, methanol, and dried to give 1-trityl-1Himidazole-4-carbonyl-Ser(tBu)-D-Hyp-Iva-Pya(4)-Cha-cMeLeu-Asn(Trt)-Lys(Boc)-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Sieberamide resin (43.0 mg, 0.01 mmol). Trifluoroacetic acid (TFA):thioanisole:m-cresol:H2O:1,2-ethanedithiol:triisopropylsilane (80:5:5:5:2.5:2.5) (0.4 mL) was added to the entire amount of the obtainedresin, then the mixture was stirred at ambient temperature for90 min, and diethyl ether was added to the reaction solution to allowprecipitation of a white powder. Diethyl ether was removed bydecantation after centrifugation of the suspension, and the procedurewas repeated to remove acid and the scavenger. The residuewas extracted with an aqueous acetic acid solution and purified bypreparative HPLC using a Daisopak-SP100-5-ODS-P column(250 20mmi.d.) to give 5.1 mgof a white powder. Mass spectrum:MALDI-TOF (a-cyano-4-hydroxycinnaminic acid, monoisotopic) [M+H]+ 1861.25 (calcd. 1861.09). Elution time on RP-HPLC: 6.43 min.Elution conditions: a Phenomenex Kinetex XB-C18 column(1.7 mm, 100 2.1 mm i.d.), linear density-gradient elution witheluents A/B = 95/5-45/55 (10 min) using 0.1% TFA in water as eluentA and 0.1% TFA-containing acetonitrile as eluent B; flow rate:0.5 mL/min. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: All peptides were synthesized in the same manner following thesynthesis procedure for 4-imidazolecarbonyl-[D-Hyp24,Iva25,Pya(4)26,Cha27,36,cMeLeu28,Lys30,Aib31]PYY(23-36) (31). Using a commerciallyavailable Sieber amide resin (391 mg, 0.25 mmol) as astarting material and the ABI 433A peptide synthesizer (DCC/HOBt0.25-mmol protocol), amino acids were successively condensed togive H-Asn(Trt)-Lys(Boc)-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-NH-Sieber Amide Resin (903 mg, 0.289 mmol/g). A 34.6-mg(0.01 mmol) aliquot of the obtained resin was weighed, washedwith DMF, and after swelling, treated with Fmoc-cMeLeu-OH(18.4 mg, 0.05 mmol), DIPCDI (8.0 lL, 0.05 mmol), and 0.5 MHOAt/DMF (0.1 mL, 0.05 mmol) in DMF for 90 min to introducecMeLeu residue on position 28. The resin was treated with 20%piperidine/DMF to remove N-terminal Fmoc group, then Cha wasintroduced on position 27 in the same manner. Pya(4), Iva,D-Hyp, Ser(tBu) and N-terminal 1-trityl-1H-imidazole-4-carboxylicacid were introduced by repeating the same steps. The resin waswashed with DMF, methanol, and dried to give 1-trityl-1Himidazole-4-carbonyl-Ser(tBu)-D-Hyp-Iva-Pya(4)-Cha-cMeLeu-Asn(Trt)-Lys(Boc)-Aib-Thr(tBu)-Arg(Pbf)-Gln(Trt)-Arg(Pbf)-Cha-Sieberamide resin (43.0 mg, 0.01 mmol). Trifluoroacetic acid (TFA):thioanisole:m-cresol:H2O:1,2-ethanedithiol:triisopropylsilane (80:5:5:5:2.5:2.5) (0.4 mL) was added to the entire amount of the obtainedresin, then the mixture was stirred at ambient temperature for90 min, and diethyl ether was added to the reaction solution to allowprecipitation of a white powder. Diethyl ether was removed bydecantation after centrifugation of the suspension, and the procedurewas repeated to remove acid and the scavenger. The residuewas extracted with an aqueous acetic acid solution and purified bypreparative HPLC using a Daisopak-SP100-5-ODS-P column(250 20mmi.d.) to give 5.1 mgof a white powder. Mass spectrum:MALDI-TOF (a-cyano-4-hydroxycinnaminic acid, monoisotopic) [M+H]+ 1861.25 (calcd. 1861.09). Elution time on RP-HPLC: 6.43 min.Elution conditions: a Phenomenex Kinetex XB-C18 column(1.7 mm, 100 2.1 mm i.d.), linear density-gradient elution witheluents A/B = 95/5-45/55 (10 min) using 0.1% TFA in water as eluentA and 0.1% TFA-containing acetonitrile as eluent B; flow rate:0.5 mL/min. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: 100mg 2-chlorotrityl resin (0.5mmol/g) was swollen in dry DCM for 30min and treated with the first building block (2.0equiv) and DIEA (4.0equiv) in dry DCM. After it was shook for 1h, 80muL MeOH was added to cap the unreacted resin for another 20min. The loaded resin was washed by DCM (3×2mL) and DMF (3×2mL). Fmoc deprotection was achieved by shaken with 2mL 20percent solution of piperidine in DMF for 20min. The following Fmoc- or Boc-amino acids (4.0equiv) was coupled using 32 HATU (4.0equiv) as coupling reagent and DIEA (8.0 equiv) as base. The mixture was shaken in DMF for 1h. After each Fmoc deprotection and coupling reaction, the resin was washed by DMF (3×2mL), DCM (3×2mL) and DMF (3×2mL). The loaded resin was washed by DCM (3×2mL) and then a solution of Pd(PPh3)4 (1.0equiv) and phenylsilane (25equiv) in 2mL anhydrous DCM was added. The mixture was shaken for 1h under the protection of dry argon. After Alloc deprotection was completed, the resin was washed by DMF (3×2mL), DCM (3×2mL) and DMF (3×2mL). After coupling of the last building block, the resin was washed by DCM (3 2 mL), DMF (3 2 mL) and DCM (5 2 mL). Then a cocktail of DCM/AcOH/TFE (v/v/v = 8:1:1) was added to the resinand shaken for 1.5 h. Then the resin was filtrated off and rinsedwith DCM (5 2 mL). The combined filtrates were concentrated under low pressure and azeotroped several times with DCM to remove the Acetic acid. The side-chain-protected peptides were obtained as white solid. |
[ 188632-07-7 ]
2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-cyclohexylpropanoic acid
Similarity: 1.00
[ 204320-60-5 ]
(R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-5-methylhexanoic acid
Similarity: 1.00
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :